Date: 2012-09-03
Type of information: R&D agreement
Compound: novel drugs in the field of CNS disorders
Company: Biofocus, a Galapagos Company (UK - Belgium) - Ono Pharmaceutical (Japan)
Therapeutic area: CNS diseases
Type agreement: R&D
Action mechanism:
Disease: CNS diseases
Details: Galapagos has announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders. Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and clinical candidates for its client.
BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all therapeutic areas with strong capability in neurodegenerative diseases, inflammatory diseases and with a growing track record of delivering candidates against rare and neglected diseases. The company has already worked with Ono Pharmaceuticals. Last year, Ono Pharmaceutical and BioFocus have signed a collaboration agreement, focused on discovering novel targets in the field of autoimmune diseases. Last May, they have also concluded an additional collaboration agreement focused on discovering novel targets in the field of allergic diseases including atopic dermatitis and bronchial asthma.
Financial terms: Financial details were undisclosed.
Latest news:
